These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 9679046)
1. Natriuretic effect of an adenosine-1 receptor antagonist in cirrhotic patients with ascites. Stanley AJ; Forrest EH; Dabos K; Bouchier IA; Hayes PC Gastroenterology; 1998 Aug; 115(2):406-11. PubMed ID: 9679046 [TBL] [Abstract][Full Text] [Related]
2. Effect of dipyridamole on kidney function in cirrhosis. Llach J; Ginès P; Arroyo V; Salmerón JM; Ginès A; Jiménez W; Gaya J; Rivera F; Rodés J Hepatology; 1993 Jan; 17(1):59-64. PubMed ID: 8423042 [TBL] [Abstract][Full Text] [Related]
3. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229 [TBL] [Abstract][Full Text] [Related]
4. Cardiovascular and renal effects of low-dose atrial natriuretic peptide in compensated cirrhosis. La Villa G; Lazzeri C; Pascale A; Sestini S; Bisi G; Sciagrà R; Vecchiarino S; Raggi VC; Barletta G; Laffi G; Gentilini P Am J Gastroenterol; 1997 May; 92(5):852-7. PubMed ID: 9149200 [TBL] [Abstract][Full Text] [Related]
5. Long-term administration of isosorbide-5-mononitrate does not impair renal function in cirrhotic patients. Salerno F; Borroni G; Lorenzano E; Solenghi D; Cazzaniga M; Bissoli F; Ceriani R; deFranchis R Hepatology; 1996 May; 23(5):1135-40. PubMed ID: 8621145 [TBL] [Abstract][Full Text] [Related]
6. Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. Fernández-Varo G; Ros J; Cejudo-Martín P; Cano C; Arroyo V; Rivera F; Rodés J; Jiménez W J Hepatol; 2003 Jun; 38(6):755-61. PubMed ID: 12763368 [TBL] [Abstract][Full Text] [Related]
7. Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis. Domenicali M; Caraceni P; Giannone F; Pertosa AM; Principe A; Zambruni A; Trevisani F; Croci T; Bernardi M Gastroenterology; 2009 Jul; 137(1):341-9. PubMed ID: 19208344 [TBL] [Abstract][Full Text] [Related]
8. Impairment of renal function during moderate physical exercise in cirrhotic patients with ascites: relationship with the activity of neurohormonal systems. Saló J; Guevara M; Fernández-Esparrach G; Bataller R; Ginès A; Jimenez W; Ginès P; Rivera F; Arroyo V; Rodés J Hepatology; 1997 Jun; 25(6):1338-42. PubMed ID: 9185749 [TBL] [Abstract][Full Text] [Related]
9. Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Wong F; Sniderman K; Liu P; Allidina Y; Sherman M; Blendis L Ann Intern Med; 1995 Jun; 122(11):816-22. PubMed ID: 7741365 [TBL] [Abstract][Full Text] [Related]
10. Taurine-induced diuresis and natriuresis in cirrhotic patients with ascites. Gentile S; Bologna E; Terracina D; Angelico M Life Sci; 1994; 54(21):1585-93. PubMed ID: 8196477 [TBL] [Abstract][Full Text] [Related]
11. Effects of captopril on renal functions, renal and portal hemodynamics in patients with cirrhosis. Tsai YT; Lin HC; Lee FY; Hou MC; Wang SS; Lee SD Proc Natl Sci Counc Repub China B; 1996 Apr; 20(2):44-50. PubMed ID: 8931343 [TBL] [Abstract][Full Text] [Related]
12. Renal hemodynamic and natriuretic effects of human atrial natriuretic factor infusion in cirrhosis with ascites. Laffi G; Pinzani M; Meacci E; La Villa G; Renzi D; Baldi E; Cominelli F; Marra F; Gentilini P Gastroenterology; 1989 Jan; 96(1):167-77. PubMed ID: 2535828 [TBL] [Abstract][Full Text] [Related]
13. Portal and systemic hemodynamics and humoral factors in cirrhosis with and without ascites. Hayes PC; Cumming AD; Craig KJ; Watson M; Bouchier IA Am J Gastroenterol; 1992 Oct; 87(10):1433-8. PubMed ID: 1415100 [TBL] [Abstract][Full Text] [Related]
14. Interrelationships between systemic hemodynamics, urinary sodium excretion, and renin-angiotensin system in cirrhosis. Aliaga L; Zozoya JM; Omar M; Mediavilla JD; Prieto J Acta Gastroenterol Belg; 1995; 58(2):213-21. PubMed ID: 7571982 [TBL] [Abstract][Full Text] [Related]
15. Effects of nitric oxide inhibition by methylene blue in cirrhotic patients with ascites. Kalambokis G; Economou M; Fotopoulos A; Bokharhii JA; Christos P; Paraskevi K; Konstantinos P; Katsaraki A; Tsianos EV Dig Dis Sci; 2005 Oct; 50(10):1771-7. PubMed ID: 16187171 [TBL] [Abstract][Full Text] [Related]
16. The use of peritoneovenous shunting in unravelling the pathogenesis of ascites in cirrhosis. Blendis LM Isr J Med Sci; 1986 Feb; 22(2):78-80. PubMed ID: 3512475 [TBL] [Abstract][Full Text] [Related]
17. Enhanced external counterpulsation: a new technique to augment renal function in liver cirrhosis. Werner D; Trägner P; Wawer A; Porst H; Daniel WG; Gross P Nephrol Dial Transplant; 2005 May; 20(5):920-6. PubMed ID: 15788437 [TBL] [Abstract][Full Text] [Related]
18. Renal sodium handling and neurohumoral systems in patients with cirrhosis in sitting posture: effects of spironolactone and water immersion. Gerbes AL; Pilz A; Wernze H; Jüngst D Clin Investig; 1993 Nov; 71(11):894-7. PubMed ID: 7906160 [TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of ascites in cirrhosis and portal hypertension. Heneghan MA; Harrison PM Med Sci Monit; 2000; 6(4):807-16. PubMed ID: 11208415 [TBL] [Abstract][Full Text] [Related]
20. Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites. Peltekian KM; Wong F; Liu PP; Logan AG; Sherman M; Blendis LM Am J Gastroenterol; 1997 Mar; 92(3):394-9. PubMed ID: 9068457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]